2011, Number 1
Cir Plast 2011; 21 (1)
Face burns to treated with early excision and covered with acelular matrix
Cuenca-Pardo J, Peralta-Conde D
PDF size: 335.45 Kb.
In the Burn Unit of the «Dr. Victorio de la Fuente Narvaez» Traumatology Hospital of the Social Security Mexican Institute, 13 patients with face burns were treated: 7 men (53.8%) and 6 women (46.2%) between 18 and 65 years old (28.8 ± 12.8 average), with superficial, partial, and total thickness burns. They were treated within 72 hours, with tangential excision of burns and covered with lyophilized pig submucosa. In superficial and partial thickness burns, epithelial regeneration was 100% in a period of 7 to 14 days (8.8 ± 2.4 average), with a strong epithelium, pink, and with no scarring. Total thickness burns had an epithelialization mainly at the edges in an area of 20 to 40% over a period of three weeks; the rest was as residual wounds with a good recipient bed for skin autografts. No patient had infections or injury extension. There were no complications. The treatment of face burns with early excision and wound coverage with pig submucosa is a very effective procedure, since the superficial and partial thickness burns, complete regeneration is achieved with a good skin cover and in the total thickness burns, it improves the recipient bed, which expedites better integration of skin grafts and reduces scarring.
Cole JK, Engrav LH, Heimbach DM et al. Early excision and grafting of face and neck burns in patients over 20 years. Plast Reconstr Surg 2002; 109(4): 1266-1273.
Engrav LH. Intrascar excision for persistent perioral hypertrophic scar. [Discussion] Plast Reconstr Surg 1996; 98(7): 1206-1207.
Felman J. Facial burns. In: McCarthy. Plastic surgery. Philadelphia: W.B. Saunders Co. 1990: 2153-2236.
Still J, Law E. Primary excision of the burn wound. Clin Plast Surg 2000; 27: 23-47.
Gravante G, Delogu D, Giordan N, Morano G, Montone A, Esposito G. The use of hyalomatriz PA in the treatment of deep partial-thickness Burns. J Burn Care Res 2007; 28: 269-274.
Hodde J, Johnson Ch. Extracellular matrix as strategy for treating chronic wounds. Am J Clin Dermatol 2007; 8: 61-66.
Barense-Hofmann MG, Doorn LP, Oskam J, Steenvoorde P. Extracellular matrix prevents split-skin grafting in selected case. J Wound Care 2007; 16: 456-458.
Gravante G, Delogu D, Giordan N, Morano G, Montone A, Esposito G. The use of hyalomatrix PA in the treatment of deep partial-thickness Burns. J Burn Care Res 2007; 28: 269-274.
Hodde J, Janis A, Hiles M. Effects of sterilization on an extracellular matrix scaffold: Part II. Bioactivity and matrix interaction. J Mater Sci Mater Med 2007; 18: 545-550.
Hodde J, Johnson CH. Extracellular Matrix as strategy for treating chronic wounds. Am J Clin Dermatol 2007; 8: 61-66.
Smith MD, Campblell RM. Use of a biodegradable patch for reconstruction of large thoracic cage defects in growing children. J Ped 2006; 41: 46-49.
Barense-H, Doorn MG, LP, Oskam J, Steenvoorde P. Extracellular matrix prevents split-skin grafting in selected case. J Wound Care 2007; 16: 456-458.
Mac Nell S. What role does the extracellular matrix serve in skin grafting and wound healing? Burns 1994: 20: s67-70.
Clark RA. Basics of cutaneus wound repair. J Dematol Surg Oncol 1993; 19: 693-706.
Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Rep Reg 2009; 17: 153-162.
Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin V3 for angiogenesis. Science 1994; 264: 569-571.
Reprager AC, Krufka A, Olwin BB. Requirement of heparin sulfate for bFGF: Mediated fibroblast growth a myoblast differentation. Science 1991; 252:1705-1708.
Walker A, Turnbull JE, Gallangher JT. Specific heparin sulfate saccharides mediate the activity of basic fibroblast growth factor. J Boil Chem 1994; 269: 931-935.
Flaumennhaft R, Rifkin DB. Extracellular matrix regulation of Growth factor and protease activity. Curr Opin Cell Biol 1991; 3: 817-823.
Brown EJ, Goodwin JL. Fibronectin receptors of phagocytes. J Exp Med 1988; 167: 777-793.
Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycans interactions. Chem Biol 2005; 12: 267-277.
Takehara K. Growth regulation of skin fibroblasts. J Demartol Sci 2000; 24: S70-77.
Tang A, Gilchrest BA. Regulation of keratinocyte growth factor gene expression in human skin fibroblast. J Dermatol Sci 1996; 11: 41-50.
Macri L, Silvertein D, Clark RAF. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv drug Deliv Rev 2007; 59: 1366-1381.
Mostow E, Haraway D, Dasling M, Hodde J, King D. Effectiveness of an extracellular matrix graft (Oasis Wound Matrix) in the treatment of the chronic leg ulcers: a randomized clinical trial. J Vasc Surg 2005; 41-5: 837-843.
Lindberg K, Badylak SF. Porcine small intestinal submucosa (SIS): bioscaffold supporting in vitro primary human epidermal cell differentiation and synthesis of basement membrane proteins. Burns 2001; 27: 254-266.
Nihsen E, Sopf D, Ernest D, Janis A, Hiles M, Johnson Ch. Absorption of bioactive molecules into Oasis wound matrix. J Wound Care 2007; 20: 541-548.
Badylak S, Liang A, Record R, Tullius R, Hodde J. Endothelial cell adherence to small intestinal submucosa an acellular bioscaffold. Biomaterial 1999; 20: 2257-2263.
Romanelli L, Dini V, Bertone M, Barbanera S, Brilli C. Oasis wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Int Wound J 2007; 4: 3-7.
Hodde JP, Ernst DMJ, Hiles MC. An investigation of the long-term bio activity of endogenous growth factor in OASIS, Wound Matrix. J Wound Care 2005; 14: 23-25.
Nissen ES, Johnson CE, Hiles MC. Bioactivity of small intestinal submucosa and oxidized regenerate cellulose/collagen. Adv Skin Wound Care 2008; 21: 479-486.
Gabriel A, Gollin G. Management of complicated gastroschesis with porcine small intestinal submucosa and negative pressure wound therapy. J Pediatr Surg 2006; 41: 1836-1840.